IMBRUVICA (ibrutinib) receives additional European Commission approval for the treatment of Waldenström's Macroglobulinemia

Janssen-Cilag UK (Janssen) announced today that the European Commission (EC) has approved IMBRUVICA® (ibrutinib) as a treatment option for adult patients with Waldenström’s Macroglobulinemia… Source link